Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C - PubMed (original) (raw)
Comparative Study
Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C
Satoru Yatsuji et al. J Gastroenterol Hepatol. 2009 Feb.
Abstract
Background and aim: Ethnic differences in non-alcoholic steatohepatitis (NASH) are well-documented, but there has been no study on the prognosis of Japanese NASH patients with cirrhosis. Accordingly, we compared cirrhotic NASH with liver cirrhosis caused by chronic hepatitis C (LC-C) to clarify its clinical features and define the risk factors for death.
Methods: A prospective evaluation of the outcomes of NASH patients with severe fibrosis was started in 1990. Data on age- and sex-matched patients with biopsy-proven LC-C were collected retrospectively and used as the control.
Results: There were 68 patients with cirrhotic NASH and 69 with LC-C. The Child-Turcotte-Pugh (CTP) class was similar in these two groups. Although the outcome of the NASH group was better than that of the LC-C group, cirrhotic NASH followed a similar course to that of LC-C; that is, complications of cirrhosis developed, including hepatocellular carcinoma (HCC; the 5-year HCC rate was 11.3% for NASH and 30.5% for HCV) and death (the 5-year survival rates were 75.2% and 73.8%, respectively). HCC was the leading cause of death in both groups (NASH, 47%; HCV, 68%). The occurrence of HCC and the CTP class were significant risk factors for mortality in NASH patients according to a multivariate analysis (HCC: hazard ratio [HR] 7.96, 95% confidence interval [CI] 2.45-25.88, CTP class A: HR 0.17, 95% CI 0.06-0.50).
Conclusion: In conclusion, the present study confirmed that cirrhotic NASH has a similar course to LC-C. The occurrence of HCC was the strongest predictor of mortality in the NASH groups. These findings may be helpful when deciding on therapeutic interventions for NASH and also for the daily management of these patients.
Similar articles
- Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Salomao M, et al. Am J Surg Pathol. 2010 Nov;34(11):1630-6. doi: 10.1097/PAS.0b013e3181f31caa. Am J Surg Pathol. 2010. PMID: 20975341 - Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis.
Toshikuni N, Izumi A, Nishino K, Inada N, Sakanoue R, Yamato R, Suehiro M, Kawanaka M, Yamada G. Toshikuni N, et al. J Gastroenterol Hepatol. 2009 Jul;24(7):1276-83. doi: 10.1111/j.1440-1746.2009.05851.x. Epub 2009 Apr 6. J Gastroenterol Hepatol. 2009. PMID: 19486451 - Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C.
Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Shiratori K. Tokushige K, et al. J Gastroenterol. 2010 Sep;45(9):960-7. doi: 10.1007/s00535-010-0237-1. Epub 2010 Apr 8. J Gastroenterol. 2010. PMID: 20376504 - Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
Tokushige K, Hashimoto E, Kodama K. Tokushige K, et al. J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:88-92. doi: 10.1111/jgh.12239. J Gastroenterol Hepatol. 2013. PMID: 24251711 Review. - Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review.
Takuma Y, Nouso K. Takuma Y, et al. World J Gastroenterol. 2010 Mar 28;16(12):1436-41. doi: 10.3748/wjg.v16.i12.1436. World J Gastroenterol. 2010. PMID: 20333782 Free PMC article. Review.
Cited by
- Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Sumida Y, et al. Diagnostics (Basel). 2020 Aug 10;10(8):579. doi: 10.3390/diagnostics10080579. Diagnostics (Basel). 2020. PMID: 32785100 Free PMC article. Review. - Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
Oda K, Uto H, Mawatari S, Ido A. Oda K, et al. Clin J Gastroenterol. 2015 Feb;8(1):1-9. doi: 10.1007/s12328-014-0548-5. Epub 2015 Jan 10. Clin J Gastroenterol. 2015. PMID: 25575848 Review. - Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Cho Y, Kim BH, Park JW. Cho Y, et al. Clin Mol Hepatol. 2023 Feb;29(Suppl):S220-S227. doi: 10.3350/cmh.2022.0360. Epub 2022 Nov 10. Clin Mol Hepatol. 2023. PMID: 36353768 Free PMC article. Review. - The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Liu Q, Bengmark S, Qu S. Liu Q, et al. Lipids Health Dis. 2010 Apr 28;9:42. doi: 10.1186/1476-511X-9-42. Lipids Health Dis. 2010. PMID: 20426802 Free PMC article. Review. - Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH).
Takaki A, Kawai D, Yamamoto K. Takaki A, et al. Int J Mol Sci. 2013 Oct 15;14(10):20704-28. doi: 10.3390/ijms141020704. Int J Mol Sci. 2013. PMID: 24132155 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical